



CERTIFICATE OF MAILING

IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: Sept 13, 2006 By: [Signature]  
Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)
Martin Dugas, et al.	) EXAMINER: Unassigned
SERIAL No.: 10/575,600	) ART UNIT: Unassigned
PCT FILING DATE: NOVEMBER 4, 2004	) Confirmation No. N/A
FOR: METHOD FOR DISTINGUISHING	) DOCKET NO 22335-US
AML-SPECIFIC FLT3 LENGTH	
<u>MUTATIONS FROM TKD MUTATIONS</u>	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.


Applicants wish to provide the USPTO with an electronic copy of WO 03/039433A2, which is in excess of 2,900 pages.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.


Respectfully submitted,

Date: 2/12/06

  
Robert W. Mann  
Reg. No. 48,555

**Correspondence Address:**  
Roche Molecular Systems, Inc  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: (510) 814-2800  
Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 22335-US	Serial No. 10/575,600
<b>LIST OF INFORMATION CITED BY APPLICANT</b> (Use several sheets if necessary)	Applicants: Martin Dugas, et al.	
	International Filing Date: Nov 4, 2004	Group: N/A



## U.S. PATENT DOCUMENTS


* EXAMINER INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
	2	5,445,934	08/29/95	Fodor, et al	435	6	09/30/92
	3	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
	4	5,700,637	12/23/97	E. Southern	435	6	04/19/94
	5	5,744,305	04/28/98	Fodor, et al	435	6	06/06/95
	6	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
	7	5,945,334	08/31/99	Besemer, et al	435	287.2	06/07/95
	8	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
	9	2003/0138793 A1	07/24/03	Su, et al	435	6	06/10/02

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
10	0 373 203 B1	08/31/94	EP			
11	0 619 321 B1	01/07/90	EP			
12	1 043 676 A1	10/11/00	EP			
13	1 109 020 A1	06/20/2001	EP			
14	WO 92/02638	02/20/92	PCT			
15	WO 03/039443 A2	05/15/03	PCT			
16	WO 2005/04316 A3	05/12/05	PCT			
17	EP 2004/012470 Search Report	06/24/06	PCT			

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

18	Alizadeh, A., et al., 1999, "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes", Cold Springs Harbor Symposium on Quantitative Biology, Volume LXIV, Cold Springs Harbor Laboratory Press, pp 71-78
19	Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines, PNAS, 97(1):262-267
20	Deutsch, J., 2003, "Evolutionary algorithms for finding optimal gene sets in microarray prediction", Bioinformatics, 19(1):45-52
21	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", Leukemia, 15:1805-1810
22	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", In Silico Biology, 2:383-391



23	Storey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarray expression data", <i>Bioinformatics</i> , 16(10):906-914
	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> , 286:531-537
25	Haeflrich, T., et al., "Abstract: The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", <i>Blood</i> , 100, Abstract 523
26	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", <i>Cold Spring Harbor Laboratory</i>
27	Kiyoi, H., et al., 2002, "FLT3 in Human Hematologic Malignancies", <i>Leukemia and Lymphoma</i> , 43(8):1541-1547
28	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> , 256:495-497
29	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", <i>Blood</i> , 100, Abstract 4287
30	Kottaridis K., et al., 2001, "Abstract: Changes in the pattern of FLT3 mutations between diagnosis and relapse restricts the potential use as markers of minimal residual disease in patients with acute myeloid leukaemia", <i>Blood</i> , 98(11-1):717a-718a
31	Lacayo, N., et al., 2002, "Abstract: Gene Expression Profiling of Pediatric Acute Myeloid Leukemia (AML) in De Novo and Relapsed Patients Reveals an Expression Signature That correlates with FLT3-Internal Tandem duplications (ITD), FLT3 Point Mutations, and KIT Point Mutations", <i>Blood</i> , 100, Abstract 310
32	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", <i>Nucleic Acids Research</i> , 31(1):82-86
33	Neben, K., et al., 2002, "Acute Myeloid Leukemia with Normal Karyotype and Mutation of the FLT3 or MLL Gene Are Characterized by Specific Gene Expression Profiles", <i>Blood</i> , 100, Abstract 2172
34	Nigro, C., et al., 2001, "Internal Tandem Duplication and D385 Mutation Analysis of FLT3 Gene in AML Patients", <i>Blood</i> , 98:11- Part 2, pp 190b
35	Schnittger, S., et al., 2002, "Networks of Molecular Mutations in Acute Myeloid Leukemia and Their Correlations to cytogenetics and Morphology", <i>Blood</i> , 100, Abstract 735
36	Schnittger, S., et al., 2002, "Acute Myeloid Leukemia (AML) with FLT3-Length Mutations (FLT3-LM) Can Be Discriminated from AML without FLT3-LM in Distinct AML-Subtypes Based on Specific Gene Expression Profiles", <i>Blood</i> , 100, Abstract 1203
37	Storey, J., et al., 2003, "Statistical significance for genomewide studies," <i>PNAS</i> , 100(16):9440-9445

EXAMINER

DATE CONSIDERED

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.